4//SEC Filing
Chrousos Phaedra 4
Accession 0001209191-21-040615
CIK 0001347178other
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 4:42 PM ET
Size
5.5 KB
Accession
0001209191-21-040615
Insider Transaction Report
Form 4
Chrousos Phaedra
Director
Transactions
- Sale
Common Stock
2021-06-14$19.34/sh−2,075$40,132→ 12,925 total
Footnotes (2)
- [F1]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001774518
Filing Metadata
- Form type
- 4
- Filed
- Jun 14, 8:00 PM ET
- Accepted
- Jun 15, 4:42 PM ET
- Size
- 5.5 KB